SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
A monoclonal antibody (mAb or moAb) is an antibody made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Coronavirus. 3d render
Lung cancer
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has Something to Prove
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell lung cancer, but experts stress the need for diverse and overall survival data.
September 18, 2024
 · 
5 min read
 · 
Kate Goodwin
Merck & Co. headquarters in Silicon Valley; Merck & Co. Inc. is an American multinational pharmaceutical company
Regulatory
FDA Approves Merck’s Keytruda for First-Line Treatment of Pleural Mesothelioma
The mesothelioma approval for the Keytruda combination regimen potentially unlocks a $12 billion market opportunity, according to a recent report from research firm IMARC Group.
September 18, 2024
 · 
2 min read
 · 
Tristan Manalac
The United States Capitol building with the dome lit up at night.
Drug pricing
Sanders Says Generics Companies Can Make, Sell Ozempic for Less Than $100 a Month
Ahead of a Senate health committee hearing next week with Novo Nordisk CEO Lars Jørgensen, Sen. Bernie Sanders claims he has secured assurances from generics developers that they will charge a significantly lower monthly price than the $969 Americans currently pay for the Danish drugmaker’s diabetes blockbuster.
September 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Novartis' office building in Marburg, Germany
Approvals
Novartis Pushes Kisqali Into Earlier Stages of Breast Cancer, Nearly Doubles Eligible Patient Population
The FDA’s approval of Kisqali in combination with an aromatase inhibitor allows Novartis to target patients with earlier breast cancer who are at risk of recurrence.
September 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: J&J's building in Switzerland
Drug pricing
HRSA Threatens J&J With Sanctions Over Planned 340B Rebate Scheme
If Johnson & Johnson refuses to scrap its proposed changes to the 340B drug pricing for hospitals, it risks the termination of participation in the program and monetary fines, the Health Resources and Services Administration warned.
September 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Podcast
Sickle Cell Gene Therapies Reach Patients, Moderna Cuts, Obesity Pill Race and ESMO 2024
Infusions of Vertex and CRISPR Therapeutics’ Casgevy and bluebird bio’s Lyfgenia have begun; Moderna targets 10 approvals through 2027; more oral obesity drug data; the latest from ESMO and more.
September 18, 2024
 · 
1 min read
 · 
Heather McKenzie
Entrance of the FTC in Washington, DC
Business
Express Scripts Sues FTC, Demands Withdrawal of ‘False and Misleading’ PBM Report
Pharmacy benefit manager Express Scripts announced Tuesday it has filed a lawsuit in federal court in Missouri against the Federal Trade Commission for its “unfair, biased and erroneous” July report on the industry.
September 17, 2024
 · 
2 min read
 · 
Kate Goodwin
Hands in black and white dropping a collection of pills on a pink background
Weight loss
Obesity Pill Race Heats Up as Novo, Roche and Terns Share Data
The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, but the comparisons are rife with confounding variables, leaving analysts unsure about where to place their bets.
September 17, 2024
 · 
4 min read
 · 
Nick Paul Taylor
3D illustration of DNA strand surrounded alien cells, abstract health science illustration
Gene Therapy
Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies
Last month, Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the company races with bluebird bio’s Lyfgenia.
September 17, 2024
 · 
2 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS